GENEURO SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.44 EUR | -1.37% |
|
-2.37% | +32.11% |
| Mar. 20 | Geneuro SA Announces Appointments of Board of Directors | CI |
| Feb. 02 | GeNeuro: share price falls after private placement | CF |
| Sales 2023 * | - | Sales 2024 * | 28.2M 29.97M | Capitalization | 43.21M 45.92M |
|---|---|---|---|---|---|
| Net income 2023 * | -11M -11.69M | Net income 2024 * | 1M 1.06M | EV / Sales 2023 * | - |
| Net Debt 2023 * | 13M 13.82M | Net Debt 2024 * | 7.9M 8.4M | EV / Sales 2024 * | 1.81 x |
| P/E ratio 2023 * |
-3.4
x | P/E ratio 2024 * |
48.7
x | Employees | 19 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 73.47% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -4.11% | ||
| 1 week | -5.08% | ||
| Current month | +1.45% | ||
| 1 month | +12.90% | ||
| 3 months | +9.38% | ||
| 6 months | +19.66% | ||
| Current year | +28.44% |
1 week
1.40
1.53
1 month
1.211.53
Current year
1.051.70
1 year
0.942.00
3 years
0.945.50
5 years
0.946.28
10 years
0.9413.72
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 05-12-31 | |
Hervé Perron
FOU | Founder | 66 | 05-12-31 |
Miguel Payró
DFI | Director of Finance/CFO | 62 | 15-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-05-26 | |
Michel Dubois
BRD | Director/Board Member | 81 | 08-07-15 |
Gordon Francis
BRD | Director/Board Member | 75 | 15-03-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-16 | 1.44 | -1.37% | 5 007 |
| 24-04-15 | 1.46 | -1.02% | 3,728 |
| 24-04-12 | 1.475 | -1.67% | 2,340 |
| 24-04-11 | 1.5 | +1.01% | 1,591 |
| 24-04-10 | 1.485 | +0.68% | 7,665 |
Real-time Euronext Paris, April 16, 2024 at 05:03 am EDT
More quotes
GeNeuro SA specializes in the development of safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis or type 1 diabetes by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. A new frontier pioneered by GeNeuro SA since 2006 and based on research by Institut Mérieux and INSERM.
Calendar
2024-04-28
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.46
EUR
Average target price
4
EUR
Spread / Average Target
+173.97%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +28.44% | 45.94M | |
| -0.10% | 42.07B | |
| +48.71% | 42.16B | |
| +4.43% | 39.77B | |
| -11.36% | 26.68B | |
| +5.67% | 24.68B | |
| -22.84% | 18.68B | |
| -0.20% | 12.11B | |
| +26.30% | 11.99B | |
| +6.91% | 11.06B |
- Stock Market
- Equities
- GNRO Stock
